(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
-2.07% ¥ 3 740.00
Live Chart Being Loaded With Signals
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies...
Stats | |
---|---|
Tagesvolumen | 323 000 |
Durchschnittsvolumen | 176 355 |
Marktkapitalisierung | 283.28B |
EPS | ¥0 ( 2024-04-10 ) |
Nächstes Ertragsdatum | ( ¥0 ) 2024-07-11 |
Last Dividend | ¥42.50 ( 2023-08-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 20.28 |
ATR14 | ¥1.742 (0.05%) |
Volumen Korrelation
Hisamitsu Pharmaceutical Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Hisamitsu Pharmaceutical Korrelation - Währung/Rohstoff
Hisamitsu Pharmaceutical Finanzdaten
Annual | 2023 |
Umsatz: | ¥141.71B |
Bruttogewinn: | ¥78.97B (55.73 %) |
EPS: | ¥181.62 |
FY | 2023 |
Umsatz: | ¥141.71B |
Bruttogewinn: | ¥78.97B (55.73 %) |
EPS: | ¥181.62 |
FY | 2022 |
Umsatz: | ¥128.33B |
Bruttogewinn: | ¥72.70B (56.65 %) |
EPS: | ¥148.00 |
FY | 2022 |
Umsatz: | ¥120.19B |
Bruttogewinn: | ¥70.07B (58.30 %) |
EPS: | ¥118.92 |
Financial Reports:
No articles found.
Hisamitsu Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0.250 (N/A) |
¥0 (N/A) |
¥0.250 (N/A) |
¥0 (N/A) |
¥42.50 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥7.00 | 2001-02-23 |
Last Dividend | ¥42.50 | 2023-08-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 42 | -- |
Total Paid Out | ¥1 175.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.73 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.60 | |
Div. Directional Score | 7.69 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8038.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
7283.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6533.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
5805.T | Ex Dividend Junior | 2023-09-28 | Sporadic | 0 | 0.00% | |
4548.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3771.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
3038.T | Ex Dividend Junior | 2023-10-30 | Annually | 0 | 0.00% | |
1925.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
9900.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
8935.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0986 | 1.500 | 8.03 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0425 | 1.200 | 8.58 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0524 | 1.500 | -0.529 | -0.793 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.22 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.66 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.45 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00455 | -1.500 | 9.92 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 731.56 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 96.01 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 96.01 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00565 | -1.500 | 9.98 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.557 | 1.000 | 4.05 | 4.05 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0929 | 1.000 | -0.142 | -0.142 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 4.86 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.431 | 0.800 | -0.460 | -0.368 | [0.5 - 2] |
Total Score | 10.77 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 20.30 | 1.000 | 8.05 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0524 | 2.50 | -0.340 | -0.793 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 96.01 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.27 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 96.01 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.894 | 1.500 | 7.38 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0514 | 1.000 | -1.216 | 0 | [0.1 - 0.5] |
Total Score | 4.60 |
Hisamitsu Pharmaceutical
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.